Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non–mTOR‐mediated etiologies-Reference-Cited by-同舟云学术

Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non–mTOR‐mediated etiologies

Published:2018-09-02 Issue:S2 Volume:3 Page:180-190
ISSN:2470-9239
Container-title:Epilepsia Open
language:en
Short-container-title:Epilepsia Open

Author:

Cepeda Carlos¹,Levinson Simon¹,Yazon Vannah‐Wila¹,Barry Joshua¹,Mathern Gary W.¹²,Fallah Aria²,Vinters Harry V.³,Levine Michael S.¹,Wu Joyce Y.⁴

Affiliation:

1. IDDRC Semel Institute for Neuroscience and Human Behavior UCLA School of Medicine University of California Los Angeles Los Angeles California, U.S.A.

2. Department of Neurosurgery David Geffen School of Medicine at University of California Los Angeles Los Angeles California, U.S.A.

3. Section of Neuropathology Department of Pathology and Laboratory Medicine and Department of Neurology David Geffen School of Medicine at University of California Los Angeles Los Angeles California, U.S.A.

4. Division of Pediatric Neurology Mattel Children's Hospital David Geffen School of Medicine at University of California Los Angeles Los Angeles California U.S.A.

Funder

Novartis

University of California, Los Angeles

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/epi4.12253

Reference49 articles.

1. Rapamycin and tuberous sclerosis complex: From Easter Island to epilepsy

2. Game of TOR — The Target of Rapamycin Rules Four Kingdoms